BsaI, GMP grade (GMP-BSA-EE101)

Catalog: GMP-BSA-EE101


Order now get it on

Product Description BsaI is designed to be used upstream of the in vitro mRNA synthesis step during mRNA therapeutics and vaccine manufacturing. As one of the type IIS restriction enzymes, it recognizes asymmetric DNA sequences and cleaves outside of their recognition sequence.
The cleavage site of BsaI is GGTCTC (N1/N5), where the GGTCTC acts as the recognition site, and the N1/N5 represents the cleavage site with a 5' overhang. Kactus provides a BSA-free reaction buffer to ensure the safety of mRNA vaccine production.
Application Molecular cloning
Plasmid linearization
Concentration 20U/µL
Unit Definition One unit is defined as the amount of enzyme required to digest 1 µg of pXba DNA in 1 hour at 37°C in a total reaction volume of 50 µL.
Source Expressed in an E.coli strain that carries the BsaI gene from Bacillus stearothermophilus.
Quality Standards Activity (Digestion activity detection): ≥ 20 kU/mL
Purity (SEC-HPLC): ≥ 95%
Residual Endonuclease: Negative
Residual Exonuclease: Negative
Residual Protease: Negative
Endotoxin: ≤ 10 EU/mL
Residual DNase: Negative
Residual RNase: Negative
Residual Host Protein: ≤ 20 ng/mg
Residual Host Cell DNA: ≤ 100 pg/mg
Residual Heavy Metal: ≤ 10 ppm
Bioburden: ≤ 1 CFU/10mL
Form Liquid
Shipping Shipping with blue ice
Stability And Storage -20±5°C for 12 months. Avoid repeated freeze-thaw cycles.
Figure 1. 1µg plasmid was added to 1 µL BsaI (lanes 1-10 diluted at 2 times gradient; lane 1 was stock solution) in a 30 minute reaction at 37°C with a total reaction volume of 20µL.
Figure 2. 1µg plasmid was added to 1µL BsaI (lane 1-12 was diluted by 2 times gradient; lane 1 was stock solution) in a 16 hour reaction at 37°C in a total reaction volume of 20µL.

You may also be interested in